Acura Pharmaceuticals filed an exhibit amending a promissory note dated November 10, 2022 with Abuse Deterrent Pharma, LLC to include additional scheduled drawdowns through the end of 2026 and restructure the document's balance, impacting the drugmaker's long-term capital obligations.